The drug is given under cycles of continuous intravenous infusion at a concentration that depends on the patient's weight (15 μg/m2/day if <45 kg; 28 μg/day if > ...

Jul 17, 2024 · There are several ongoing and completed clinical trials exploring the safety and effectiveness of combining mAbs with infusions of autologous or allogeneic NK ...

Dec 10, 2018 · The cause specific hazard rate for chronic GVHD will be compared between alternative donor groups using the Cox proportional hazards model ...

The recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75 mg/m2 of body ...

Patients with acute leukemia or chronic myelogenous leukemia ... *If infusion occurs over 2 days, the day of transplant should be recorded as the day the first ...

Nov 19, 2018 · This pilot trial suggests the favorable efficacy of the hyper-CVDD chemotherapy as a frontline remission induction regimen before transplantation.

Autologous and allogeneic hematopoietic stem cell transplantation (HCT) has been used to treat lymphoma for more than 10 years, much of that time in the ...

Study Design: The study is designed as a Phase III, multicenter trial comparing outcomes after allogeneic hematopoietic stem cell transplantation (HCT) for ...

Oct 14, 2022 · - If the patient cannot receive the LID2 or the first S64315 C1D2 dose due to an AE, the S64315 infusion. (either LID2 or C1D2) may be ...

Mar 14, 2022 · Results of clinical trials in hematological malignancies are presented, and strategies on how to improve the clinical outcome of NK cell therapy ...